Waves of targeted job cuts are continuing into 2025 across pharma and biotech as companies respond to pipeline setbacks, patent cliffs and shifting regulatory landscapes. Reductions to workforces are being propelled by financial pressures and strategic realignments, as companies grapple with revenue losses from patent expirations and decide to redirect their focus. Meanwhile, an unpredictable […]